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Abstract
Introduction: Lung involvement is a common extra-articular manifestation of rheumatoid arthritis (RA) that confers 
significant morbidity and mortality. The objective of the present study is to assess which respiratory symptoms and 
patient and disease characteristics are most highly associated with pulmonary function test (PFT) abnormalities in an 
RA patient cohort without clinical cardiovascular disease.
Methods: A total of 159 individuals with RA and without clinically evident cardiovascular disease were evaluated. 
Respiratory symptoms were assessed with the Lung Tissue Research Consortium questionnaire and all patients 
underwent evaluation with PFTs. Demographic, lifestyle, RA disease and treatment characteristics were collected. 
Subclinical coronary artery disease was assessed by cardiac computed tomography. Multivariable regression analysis 
was used to identify pulmonary symptoms and nonpulmonary parameters associated with PFT abnormalities. Areas 
under the receiver operating characteristic curves (AUC) were calculated to evaluate the discrimination of these 
variables for identifying patients with PFT abnormalities.
Results: Respiratory symptoms were reported by 42% of the patient population. Although only 6% carried a prior 
diagnosis of lung disease, PFT abnormalities were identified in 28% of the subjects. Symptoms combined with other 
patient and RA characteristics (body mass index, current smoking, anti-cyclic citrullinated peptide antibodies, and 
current prednisone use) performed satisfactorily in predicting the PFT abnormalities of obstruction (AUC = 0.91, 95% 
confidence interval = 0.78 to 0.98), restriction (AUC = 0.79, 95% confidence interval = 0.75 to 0.93) and impaired 
diffusion (AUC = 0.85, 95% confidence interval = 0.59 to 0.92). Co-morbid subclinical coronary artery disease did not 
modify these relationships.
Conclusions: Assessment of respiratory symptoms along with a limited number of clinical parameters may serve as a 
useful and inexpensive clinical tool for identifying RA patients in need of further pulmonary investigation.
Introduction
Rheumatoid arthritis (RA) is a highly inflammatory
chronic disease associated with diminished physical
function and premature mortality [1-5]. Lung involve-
ment is a common extra-articular manifestation of RA
[6], conferring significant morbidity and mortality [7].
Interstitial lung disease (ILD) is the most common and
most serious form of lung involvement in RA. The
reported prevalence of subclinical and clinically evident
ILD in RA varies depending on the method of detection,
and ranges between 1 and 58% [8-12]. Radiographic
changes and changes on pulmonary function testing may
precede overt symptoms by years. Once clinically appar-
ent, ILD is associated with significant mortality [13].
Respiratory diseases (including ILD) are a leading cause
of excess death in patients with RA [14].
Chronic obstructive pulmonary disease has also been
reported to occur more frequently in patients with RA
than in the general population after adjusting for smok-
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ing, and to have a greater impact on survival [15,16]. Both
restrictive lung disease (ILD) and obstructive lung disease
thus produce clinically important effects in patients with
RA.
Given the impact of lung disease on morbidity and
mortality in RA, screening of asymptomatic RA patients
for pulmonary involvement has been recommended by
some experts [17-19]. The most sensitive method for
detecting ILD is high-resolution computed tomography
(HRCT) of the chest - but this technique is expensive and
associated with significant radiation exposure [20], limit-
ing its suitability for screening of asymptomatic individu-
als. Pulmonary function testing has proved valuable in
early detection of RA-associated lung disease. Neverthe-
less, the cost of screening all asymptomatic RA patients
with pulmonary function tests (PFTs) makes this
approach untenable. Clinicians may therefore rely on
development of overt respiratory symptoms (for example,
dyspnea or cough) and/or physical findings (for example,
basilar crackles) in RA patients as the trigger for evalua-
tion for lung disease, an approach endorsed by the British
Society of Rheumatology [19,21]. This approach has lim-
ited the understanding of the natural history of RA-asso-
ciated lung disease by identifying patients primarily later
in disease, and has contributed to the difficulty in assess-
ing therapeutic agents for lung disease. Further, respira-
tory symptoms are not specific for pulmonary disease
and could represent cardiovascular disease (CVD). Car-
diovascular events, including myocardial infarctions and
congestive heart failure, are increased twofold to fourfold
in RA patients compared with matched non-RA controls
[3,5,22,23].
Several studies have evaluated associations between
patient-reported respiratory symptoms and lung involve-
ment in RA with conflicting results [10,12,17]. Overall,
these studies suggest that pulmonary complaints, physi-
cal findings and certain RA-related or other patient char-
acteristics may be more common in patients with
documented lung disease than in patients without. These
studies largely focused on individual predictors rather
than multifactor prediction model, on restrictive disease
only, and on structural (HRCT) rather than physiological
(PFT) outcome [10,12,17]. Further, these studies did not
take into account potential confounding by co-morbid
CVD [10,12,17].
We investigated the association of systemically assessed
respiratory symptoms and patient and RA-related vari-
ables with impaired pulmonary function in a well-charac-
terized cohort of 159 RA patients free of clinically evident
CVD. We evaluated whether subclinical coronary artery
disease (CAD) may confound these relationships. We
sought to identify respiratory symptoms and additional
patient characteristics that, alone or in combination, dis-
criminated patients with PFT abnormalities.
Materials and methods
Participants and enrollment
The study subjects were participants in the Evaluation of
Subclinical Cardiovascular Disease and Predictors of
Events in Rheumatoid Arthritis, a cohort study investi-
gating the prevalence, progression, and risk factors for
subclinical CVD in RA patients described previously [24].
Participants were 45 to 84 years of age at enrollment and
met the American College of Rheumatology (formerly the
American Rheumatism Association) 1987 classification
criteria for RA [25]. Exclusion criteria were known prior
CVD, defined as a prior history of self-reported physi-
cian-diagnosed myocardial infarction, heart failure, coro-
nary artery revascularization, angioplasty, peripheral
vascular disease or procedures (excluding varicose vein
procedures), implanted pacemaker or defibrillator
devices, and current atrial fibrillation. The study was
approved by the Institutional Review Board of the Johns
Hopkins Hospital, with all subjects providing written
informed consent.
Assessments
All clinical and PFT data utilized for this study were from
Visit 2, which took place approximately 18 months after
the baseline visit. The evaluation for coronary artery cal-
cification took place at the baseline visit.
Measurement of the primary outcome
Pulmonary function testing constituted the primary out-
come and included spirometry, lung volumes and diffu-
sion capacity according to American Thoracic Society
criteria [26]. Obstruction was defined as a forced expira-
tory volume in the first second/forced vital capacity ratio
≤90% of the predicted ratio. Restriction was defined as a
forced vital capacity < 80% of predicted in the absence of
concomitant obstructive abnormality. Isolated impaired
diffusion capacity was defined by a diffusion capacity <
80% of predicted, in the absence of obstruction or restric-
tion. One hundred and eighty patients completed Visit 2.
Of these patients, 159 (88%) had pulmonary function
testing completed. The remaining 21 patients were
unable to be tested due to logistical considerations.
Assessment of respiratory symptoms
The Lung Tissue Research Consortium questionnaire
(Additional file 1) [27] was administered by an inter-
viewer during Visit 2 to assess respiratory symptoms.
This form includes Items 7 to 13 from the American Tho-
racic Society Division of Lung Diseases Questionnaire
(ATS-DLD-78-C) [28], focusing on cough, phlegm,
wheezing and dyspnea. This questionnaire meets Ameri-
can Thoracic Society criteria for epidemiologic surveys in
chronic respiratory diseases [29] and is considered repro-
ducible, valid and free of bias [28].Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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Measurement of subclinical cardiovascular disease
Subclinical CAD was assessed at the baseline visit by car-
diac multi-row detector computed tomography according
to a standard previously published methodology [30].
Coronary artery calcium was quantified using the Agat-
ston method [31]. A phantom of known calcium density
was scanned simultaneously with the patient for stan-
dardization [32]. Intra-observer and inter-observer
agreement for computed tomography assessments has
been evaluated and found to be high (kappa = 0.93 and
0.90, respectively) [33]. An Agatston coronary calcium
score ≥100, shown to correlate with the presence of
plaque and moderate risk for future cardiovascular
events, was used as a cut-off value to identify patients
with significant subclinical CAD [34,35].
Pre-existing diagnoses of lung disease
At the time of PFT and respiratory symptom assessment
(Visit 2), patients were asked: 'Has a doctor told you that
you have developed any of the following: emphysema,
asthma. Has a physician ever diagnosed you with rheu-
matoid lung disease (other than pulmonary nodules).'
Patient-reported diagnoses were not independently veri-
fied.
Demographic and lifestyle covariates
Demographic and lifestyle characteristics, including cur-
rent or past smoking, were collected via examiner-admin-
istered questionnaires. Physical function was assessed
with detailed questions investigating the amount and
intensity of intentional exercise and was calculated in
minutes/week and metabolic equivalents/week. Func-
tional levels were assessed using the Stanford Health
Assessment Questionnaire (HAQ) score [36]. The body
mass index (BMI) was calculated as kilograms per meter2.
RA-specific covariates
RA disease duration was calculated from the date of diag-
nosis. The RA Disease Activity Score in 28 joints was cal-
culated, including C-reactive protein [37]. Joints were
examined for swelling and tenderness by a single trained
examiner. The extent of radiographic joint damage was
assessed at the baseline visit by a trained radiologist using
the modified Sharp Score [38]. Information regarding
treatment with biologic and nonbiologic disease-modify-
ing antirheumatic drugs and steroids was collected via
detailed questionnaires. All current medication was
brought to Visit 2 and the medications and dosages were
recorded by research staff.
Laboratory covariates
Fasting sera and plasma were stored at -70°C. Serum C-
reactive protein levels were measured by high-sensitivity
nephelometry (Dade Behring, Deerfield, IL, USA). Rheu-
matoid factor (RF) and anti-cyclic citrullinated peptide
(anti-CCP) antibodies were determined by ELISA with
cut-off values for seropositivity being ≥40 units and ≥60
units, respectively.
Statistical analysis
In initial exploratory data analysis, the distributions of all
variables were examined. Means and standard deviations
were calculated for normally distributed continuous vari-
ables, medians and interquartile ranges for non-normally
distributed continuous variables, and counts and per-
centages calculated for categorical variables. Differences
in patient characteristics for the group with abnormal
PFTs were compared versus the group with normal PFTs
using t tests for means, the Kruskal-Wallis test for medi-
ans, and the chi-square goodness-of-fit or Fisher's exact
test (as appropriate) for proportions.
Receiver operator characteristic (ROC) curves were
constructed to examine the ability of pulmonary symp-
toms to predict PFT abnormalities. Informative tests are
defined by an area under the curve (AUC) for a resulting
ROC function ≥0.5. Predictors that classify every individ-
ual within the sample perfectly result in an AUC of 1.0
[39]. The ROC curve was considered internally valid if
the 95% confidence interval (CI) using the bootstrap
method did not contain 0.5 (that is, < 50% chance of
being uninformative) [40].
Multivariable logistic regression models were expanded
to include the pulmonary symptoms from each category
(cough, phlegm, wheezing, and breathlessness) with the
highest AUC from the univariate models, as well as socio-
demographic characteristics, measures of coronary calci-
fication, RA disease and treatment characteristics, and
pa t ie n t  r eport  of  prio r lu ng disease .  Sim pli fied m ode ls
including only pertinent predictors of PFT outcomes
were obtained using hierarchical modeling techniques,
with the likelihood ratio test used to exclude predictors
lacking any contribution to the variability of the outcome.
From the variables identified in the final predictive
models, ROC curves were constructed for models includ-
ing only reported symptoms, including symptoms + per-
tinent sociodemographic and RA characteristics, and
including symptoms + pertinent characteristics + self-
reported lung disease. A UCs for these correlated ROC
curves were compared using the nonparametric method
of DeLong and colleagues [41]. Two correlated ROC
curves with statistically different AUCs indicate that the
additional covariates included in the model significantly
improved the performance of the model to discriminate
the outcome.
Statistical calculations were performed using Inter-
cooled Stata 10.1 (StataCorp, College Station, TX, USA).
In all tests, a two-tailed α level of 0.05 was defined as the
level of statistical significance.
Results
The mean age of the cohort was 61 years. The majority of
patients were Caucasian (86%) and female (61%), and the
median duration of disease was 10.7 years. Two-thirds ofPappas et al. Arthritis Research & Therapy 2010, 12:R104
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the patients were positive for RF (62%) and for CCP
(66%). Disease activity in the cohort was mild to moder-
ate (median RA Disease Activity Score in 28 joints score
= 3.1) and the mean HAQ score (0.75) indicated mild dis-
ability. The majority of patients were receiving disease-
modifying antirheumatic drugs - methotrexate being
most common (68%), followed by TNF inhibitors (42%)
and prednisone (37%). Ninety-two patients (58%) in the
cohort had a history of smoking.
At the time of the present analysis, 158 patients in the
cohort had completed PFT testing: 45 (28%) demon-
strated at least one predefined abnormality. Restrictive
lung disease was observed in 12 patients (7.6%) (median
forced vital capacity = 71% of predicted; range 63 to 76%),
obstructive lung disease in 18 patients (11.3%) (median
forced expiratory volume in the first second/forced vital
capacity ratio = 85% of predicted ratio; range 79 to 88%)
and impaired diffusing capacity in 31 patients (19.8%).
Impaired diffusion in conjunction with restriction or
obstruction was observed in 16 of those latter subjects,
while the remaining 15 patients (9.6%) had isolated
impaired diffusion (median diffusion capacity of the lung
for carbon monoxide = 69% of predicted, range 59 to
75%). We found no differences in general demographics,
pulmonary symptoms or medication use between the 38
patients who did not undergo testing compared with
those who did. There was a higher rate of reported prior
diagnosis of emphysema and a higher frequency of posi-
tive CCP and RF among patients who did not undergo
PFT testing.
Patient characteristics according to the presence of any
PFT abnormalities are summarized in Table 1. Only 17
(37.8%) of the 45 patients with abnormal PFTs reported a
prior known diagnosis of emphysema (eight patients),
asthma (eight patients) or rheumatoid lung disease (two
patients). Demographic characteristics did not differ
among those with and without PFT abnormalities; how-
ever, the proportion of current smokers was almost three-
fold higher in patients with PFT abnormalities compared
to the group without (22% vs. 8%, respectively; P = 0.012).
Significant coronary calcification (coronary artery cal-
cium > 100) was more prevalent in patients with PFT
abnormalities compared to those without abnormal PFTs
(42% vs. 30%, respectively), but was not statistically sig-
nificant (P = 0.14).
Among RA characteristics, seropositivity for RF (P =
0.011) and for anti-CCP (P = 0.003), and current use of
glucocorticoids (P = 0.018) were significantly higher in
patients with PFT abnormalities. The specific diagnosis
for which glucocorticoids were prescribed could not be
determined. There were no significant differences in
terms of RA disease activity or HAQ scores, but there is a
trend toward a higher Sharp score (P < 0.06) in patients
on corticosteroids. We find no difference in pulmonary
symptoms between patients based on prednisone use.
There is a significantly higher rate of prior diagnosis of
emphysema in patients not on steroids (P < 0.001).
Patients with restriction had a statistically higher
median C-reactive protein (P  = 0.04) than the normal
PFT group.
Pulmonary symptoms were reported in 78 patients
(42%). Patients with PFT abnormalities were significantly
more likely to report pulmonary symptoms (58% vs. 36%,
respectively; P = 0.012) in all categories assessed (cough,
phlegm, wheezing, and breathlessness).
Association of pulmonary symptoms with patterns of 
pulmonary function test abnormalities
ROC curves for the association of individual pulmonary
symptoms and PFT abnormalities are summarized in
Table 2. Sensitivities and specificities are also summa-
rized in Additional file 2. AUCs are depicted only for
those models demonstrating internal validity. Within
each category of symptoms, multiple symptoms were
associated with any PFT abnormality but no single symp-
tom resulted in AUC > 0.63, indicating that individual
pulmonary symptoms alone were generally poor predic-
tors of PFT abnormalities. Within each category of symp-
toms, frequent cough, chronic phlegm, frequent
wheezing, and breathlessness after 100 yards of level
walking demonstrated the highest AUCs for predicting
abnormal PFTs and were used in subsequent multivari-
able modeling.
When specific PFT abnormalities were considered sep-
arately, breathlessness with level walking demonstrated
the highest AUC for restriction (0.661, 95% CI = 0.509 to
0.828). For obstruction, both cough and wheezing were
informative, with an AUC for chronic cough of 0.617
(95% CI = 0.512 to 0.746) and an AUC for any wheezing
of 0.626 (95% CI = 0.510 to 0.761). For isolated impaired
diffusion, symptoms of cough, phlegm, wheezing, and
breathlessness all provided valid prediction, with AUCs
for morning cough (0.646, 95% CI = 0.559 to 0.739), for
chronic phlegm (0.658, 95% CI = 0.576 to 0.749), for any
wheezing (0.623, 95% CI = 0.534 to 0.727), and for breath-
lessness with hurrying or walking on an incline (0.602,
95% CI = 0.513 to 0.699) demonstrating the highest val-
ues.
Performance of combining pulmonary symptoms with 
patient characteristics to predict presence of any 
pulmonary function test abnormalities
Multivariable predictors of the presence of any PFT
abnormalities were modeled, including the pulmonary
symptoms identified from Table 2, along with other
potential nonpulmonary predictors (Table 3). Among
these, the predictors retained in the final model (Table 3,
Model 3) included two pulmonary symptoms (chronicPappas et al. Arthritis Research & Therapy 2010, 12:R104
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phlegm and breathlessness with walking 100 yards),
patient report of a prior diagnosis of lung disease and
four other characteristics (BMI, current smoking, sero-
positivity for anti-CCP antibodies, and current predni-
sone use), resulting in the following prediction equation:
In this equation, for all predictors except BMI, a value
of 1 would be entered for a patient with the predictor;
otherwise, 0 would be entered. For BMI, the actual value
of the patient's BMI would be used.
The AUC for the ROC curve including only the two sig-
nificant pulmonary symptoms was 0.612 (95% CI = 0.529
to 0.693; Table 4), indicating that the combination of
symptoms was only slightly better than each individually
i n  p r e d i c t i n g  a n y  a b n o r m a l  P F T s .  A d d i t i o n  o f  c u r r e n t
smoking, BMI, anti-CCP seropositivity, and current pred-
nisone use to the model increased the AUC to 0.773 (95%
CI = 0.679 to 0.857). This ROC curve obtained from the
extended model was statistically different from the symp-
tom-only model (P = 0.0006). Although adding patient
report of lung disease to the extended model increased
the AUC of the ROC curve slightly (0.799, 95% CI = 0.709
to 0.873), the ROC curves did not statistically differ (P =
Natural log of the odds of any abnormal PFTs ch =− + 08 5 14 3 .. ( r ronic phlegm breathlessness with
 yards of walkin
). ( +17 9
100 g g current smoking BMI anti CCP positive ). ( ). ( ). ( +− + − 13 9 00 8 10 4 ) ). (
). ( )
+
+
09 7
13 3
current
prednisone use reported lung disease
Table 1: Patient characteristics according to the presence of any pulmonary function abnormalities
Characteristic No PFT abnormalities (n = 114) PFT abnormalities (n = 45) P value
Age (years) 61 ± 7.7 63 ± 9.9 0.14
Male gender 41 (36) 21 (47) 0.21
Caucasian 99 (87) 37 (82) 0.46
Body mass index (kg/m2) 29 ± 5.0 28 ± 5.5 0.12
Ever smoker 63 (55) 29 (64) 0.29
Current smoker 9 (7.9) 10 (22) 0.012
Reported lung disease 13 (11) 17 (38) < 0.001
Emphysema 2 (1.8) 8 (18) < 0.001
Asthma 12 (11) 8 (18) 0.22
Rheumatoid lung disease 0 (0) 2 (4.7) 0.07
CAC > 100 34 (30) 19 (42) 0.14
RA characteristics
RA duration (years) 9.9 (5.6 to 18) 11 (7.1 to 23) 0.16
RF seropositive 64 (56) 35 (78) 0.011
Anti-CCP seropositive 67 (59) 37 (84) 0.003
DAS28 (units) 3.1 (2.4 to 3.7) 3.1 (2.4 to 4.2) 0.74
HAQ (units) 0.75 (0.13 to 1.5) 0.88 (0.13 to 1.5) 0.48
Modified Sharp Score (units) 41 (12 to 99) 56 (25 to 140) 0.098
Current prednisone 35 (31) 23 (51) 0.018
Current nonbiologic DMARDs 99 (88) 38 (84) 0.60
Current biologic DMARDs 55 (49) 20 (44) 0.63
Reported pulmonary symptoms
Any reported symptoms 41 (36) 26 (58) 0.012
Any cough 19 (17) 16 (36) 0.010
Any phlegm 22 (19) 16 (36) 0.030
Any wheezing 17 (15) 18 (42) 0.001
Any breathlessness 18 (16) 15 (33) 0.014
Data expressed as mean ± standard deviation, n (%) or median (interquartile range). CAC, coronary artery calcium; CCP, cyclic citrullinated 
peptide; DAS28, RA Disease Activity Score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; PFT, pulmonary function test; RA, 
rheumatoid arthritis; RF, rheumatoid factor.Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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0.26). Similarly, exclusion of patients with a prior diagno-
sis of lung disease did not alter the performance of the
extended model compared with the full cohort. Based on
the algorithm developed, a schematic for identifying
patients for screening with PFTs is provided in Figure 1
and the probabilities for abnormal PFTs given different
combinations of predictors are outlined in Additional file
3.
We performed multivariable models for the prediction
of specific PFT abnormalities (restriction, obstruction,
impaired diffusion) (Additional file 4). For restriction,
one symptom (breathlessness with level walking) and two
patient characteristics (BMI and current prednisone use)
were retained in the final prediction equation. The AUC
for the ROC curve for the model including all three pre-
dictors was 0.786 (95% CI = 0.585 to 0.918) (Table 5) and
differed significantly from the ROC curve that included
pulmonary symptoms only (P = 0.046).
For obstruction, eight predictors were retained in the
final model (Additional file 4), including one symptom
(chronic cough), prior diagnosis of lung disease, and six
other characteristics (gender, exercise, BMI, current
smoking, RF seropositivity, and current prednisone use).
The AUC for the ROC curve including chronic cough,
gender, exercise, BMI, smoking, and prednisone use was
0.905 (95% CI = 0.784 to 0.978) (Table 5) and was signifi-
cantly higher than the model including only chronic
cough (P = 0.0001). Addition of reported prior lung dis-
ease to the extended prediction model increased the AUC
to 0.961 (95% CI = 0.908 to 0.992); however, the differ-
ence between the ROC curves was not statistically signif-
icant (P = 0.080).
For impaired diffusion, six predictors were retained in
the final model (Additional file 4), including one symp-
tom (chronic phlegm), prior diagnosis of lung disease,
and four other characteristics (age, BMI, current smok-
ing, and current prednisone use). The AUC for the
extended model including chronic phlegm, age, BMI,
smoking, and current prednisone was 0.852 (95% CI =
0.749 to 0.934) (Table 5), and differed significantly from
the model including chronic phlegm only (P = 0.0003).
The addition of reported pulmonary disease was associ-
Table 2: Receiver operator characteristics for individual reported pulmonary symptoms to predict the presence of PFT 
abnormalities
Pulmonary symptom Any PFT abnormalitya Restrictiona Obstructiona Impaired diffusiona
AUC 95% CIb AUC 95% CIb AUC 95% CIb AUC 95% CIb
Cough
Frequentc 0.60 (0.53 to 0.67)d - - 0.61 (0.53 to 0.70)
Morning 0.57 (0.50 to 0.64) - 0.62 (0.51 to 0.74) 0.65 (0.56 to 0.74)d
Daytime or night 0.57 (0.50 to 0.66) - - 0.59 (0.51 to 0.68)
Chronice - - 0.62 (0.51 to 0.75)d 0.61 (0.52 to 0.71)
Phlegm
Frequentc - - - 0.59 (0.52 to 0.67)
Morning - - - 0.60 (0.52 to 0.70)
Daytime or night 0.57 (0.51 to 0.63) - - 0.61 (0.53 to 0.70)
Chronice 0.59 (0.53 to 0.67)d - - 0.66 (0.58 to 0.75)d
Wheezing
Any 0.58 (0.53 to 0.65) - 0.63 (0.51 to 0.76)d 0.62 (0.53 to 0.73)d
Oftenf 0.63 (0.56 to 0.71)d ---
Breathlessness
Hurrying or walking on incline 0.56 (0.51 to 0.63) 0.66 (0.51 to 0.80) - 0.60 (0.51 to 0.70)d
With level walking at own pace 0.57 (0.51 to 0.64) 0.66 (0.51 to 0.81)d - 0.59 (0.50 to 0.67)
After 100 yards of level walking 0.60 (0.52 to 0.67)d --
PFT, pulmonary function test. aAreas under the curve (AUCs) are reported only for internally valid models; that is, those in which the 95% 
confidence interval (CI) did not include 0.5 (uninformative). b95% CI obtained with repeated sampling and calculation of the AUC for 1, 000 
bootstrap resamples with replacement. cDefined as much as four to six times per day, 4 days or more per week. dSymptoms selected for inclusion 
in subsequent multivariable modeling. eDefined as on most days for at least 3 consecutive months per year. fDefined as on most days or nights.Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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ated with a slight increase in AUC (0.864, 95% CI = 0.737
to 0.936), but was not significantly different than the
model not including reported pulmonary disease.
For all models, AUCs for the ROC curves were not sub-
stantially reduced when the cohort was restricted to
patients who did not report a prior diagnosis of pulmo-
nary disease (Table 5).
Discussion
Timely recognition of the pulmonary manifestations of
RA is critical in light of the fact that respiratory involve-
ment is identified as the second leading cause of mortality
in patients with RA. Pulmonary disease in RA patients
may not be routinely sought by rheumatologists and
internists in the absence of cost-effective, accurate and
time-efficient means of screening. An adequate screening
tool that could easily be integrated into clinical care
would represent a critical step in early identification and
treatment of these conditions. In the present study, we
demonstrated that pulmonary symptoms in combination
with other easily measured variables can predict PFT
abnormalities in patients with RA, and can identify
patients in greatest need of further workup.
Nearly one-third of subjects in this prospective RA
cohort demonstrated PFT abnormalities, and the major-
ity of these patients carried no prior pulmonary diagno-
sis. As might be expected, respiratory symptoms were
statistically more common in patients with abnormal
PFTs. Specific symptoms in combination with commonly
assessed patient characteristics were highly predictive of
Table 3: Multivariate associations of pulmonary symptoms, cardiac findings, and patient characteristics with any PFT 
abnormality
Characteristic Model 1 (null) Model 2 (complex) Model 3a (simplified) P value
OR 95% CI OR 95% CI OR 95% CI
Frequent cough 1.61 (0.49 to 5.25) 2.05 (0.41 to 10.3)
Chronic phlegm 2.64 (0.87 to 8.02) 3.01 (0.56 to 16.3) 4.16 (1.21 to 14.4) 0.02
Frequent wheezing 2.84 (0.74 to 10.9) 2.12 (0.37 to 12.1)
Breathlessness at 100 yards 2.24 (0.60 to 8.32) 11.2 (1.54 to 81.6) 5.96 (1.25 to 28.3) 0.03
Reported diagnosis of pulmonary disease 4.57 (1.35 to 15.4) 3.77 (1.42 to 10.0) 0.01
CAC >100 1.25 (0.38 to 4.11)
Age, per year 1.04 (0.97 to 1.12)
Male vs. female 0.87 (0.27 to 2.84)
White vs. other race 0.69 (0.20 to 2.31)
Reported exercise, per quartile 0.95 (0.57 to 1.57)
BMI, per kg/m2 0.91 (0.82 to 1.00) 0.93 (0.85 to 1.01) 0.08
Current smoking 5.34 (1.12 to 25.4) 4.01 (1.22 to 13.3) 0.02
Ever smoking vs. never smoking 0.73 (0.23 to 2.31)
RA duration, per year 1.01 (0.95 to 1.07)
RF seropositivity 1.53 (0.44 to 5.29)
Anti-CCP seropositivity 2.99 (0.69 to 12.9) 2.82 (0.96 to 8.29) 0.06
DAS28, per unit 0.78 (0.45 to 1.33)
HAQ, per unit 0.86 (0.35 to 2.10)
Log-modified Sharp score, per log unit 1.16 (0.71 to 1.91)
Current prednisone use 2.54 (0.95 to 6.85) 2.65 (1.12 to 6.25) 0.03
Current nonbiologic use 0.38 (0.08 to 1.88)
Current biologic use 0.82 (0.27 to 2.52)
Model 1 (null), pulmonary symptoms only; Model 2 (complex), multivariable model with extended covariate list; Model 3, multivariate model with 
covariates reduced based on hierarchical modeling. BMI, body mass index; CAC, coronary artery calcium; CCP, cyclic citrullinated peptide; CI, 
confidence interval; DAS28, RA Disease Activity Score in 28 joints; HAQ, Health Assessment Questionnaire; OR, odds ratio; PFT, pulmonary 
function test; RA, rheumatoid arthritis; RF, rheumatoid factor. aP value for the likelihood ratio test comparing Models 2 and 3 = 0.801, indicating 
that the simpler model was not statistically different in predicting the variance in the outcome than the more complex model.Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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PFT abnormalities. We conclude that, beyond smoking,
factors such as positive RF and anti-CCP antibodies and
ongoing corticosteroid treatment may, in combination
with pulmonary symptoms, identify individuals in need
of further pulmonary evaluation. A simplified schematic
of this screening approach (Figure 1) indicates how these
findings might guide subsequent evaluation with PFTs.
The findings of our study are supported by prior studies
that have identified individual factors in association with
lung disease. High titers of anti-CCP antibodies have
been associated with the presence of pulmonary fibrosis
in patients with RA [42]. The association of corticoster-
oid use with PFT abnormalities could be related to the
effects of the drug itself or, more probably, identifies
patients with severe or difficult to treat RA, a known risk
factor for PFT abnormalities [16,43]. In the present study
we were unable to determine the diagnosis for which cor-
ticosteroids were prescribed. Corticosteroid use may
therefore be a marker of RA disease activity or a marker
of lung disease.
Previous studies have reported association of symp-
toms and/or patient and disease characteristics with lung
Table 4: Receiver operator curve validation of multivariable models predicting the presence of any abnormal PFTs
Full cohort (n = 159) Cohort excluding reported lung disease 
(n = 129)
AUC 95% CIa P value AUC 95% CIa P value
Symptoms onlyb 0.61 (0.53 to 0.69) - 0.64 (0.55 to 0.76) -
Symptoms + other factorsc 0.77 (0.68 to 0.86) 0.0006* 0.79 (0.67 to 0.89) 0.005*
Symptoms + factors + lung diseased 0.80 (0.71 to 0.87) 0.26** - - -
PFT, pulmonary function test. a95% confidence interval (CI) obtained with repeated sampling and calculation of area under the curve (AUC) 
for 1,000 bootstrap resamples with replacement. bSymptoms included were those from the final predictive multivariable model (chronic 
phlegm and breathlessness with ambulating 100 yards). cOther factors included were those from the final predictive multivariable model 
(current smoking, body mass index, presence of anti-cyclic citrullinated peptide antibodies, and current prednisone use). dLung disease 
includes patient self-report of emphysema, asthma, and rheumatoid lung disease. *P values represent the comparison of AUC functions for 
the symptoms + other factors model vs. the symptom-only model. **P values represent the comparison of AUC functions for the symptoms 
+ factors + lung disease model vs. the symptoms + factors model.
Figure 1 Schematic of screening for a patient with rheumatoid arthritis and without known lung disease. Application of the described algo-
rithm to a model patient demonstrates how the probability of pulmonary function test (PFT) abnormality varies with specific patient features. See 
Additional file 3 for calculated probabilities based on the presence of different combinations of predictors. CCP, cyclic citrullinated peptide.
CCP positive
Current Smoker
Prednisone use
Phlegm and dyspnea
present
Probability of abnormal
PFTs = 94.3%
Probability of abnormal
PFTs = 97.7%
Probability of abnormal
PFTs = 85.3%
PFTs
Probability of abnormal
PFTs = 59.3%Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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disease in RA patients. Our results are not directly com-
parable given differences in primary outcome and tar-
geted population. Dawson and colleagues [10] detected
no difference in the prevalence of respiratory symptoms
(dyspnea New York Heart Association grades II and III
and productive cough) in 28 patients with HRCT-docu-
mented ILD compared to 122 patients without [10]. Gab-
bay and colleagues a priori divided 36 early RA patients
based on symptoms, PFT and HRCT results, but did not
test predictor variables against a uniform outcome [12].
The study by Gochuico and colleagues enrolled 64 RA
patients without respiratory symptoms [17], and thus was
primarily focused on identifying prevalence and predic-
tors of pulmonary disease in asymptomatic RA patients.
A number of isolated factors have been found to associate
with ILD in RA patients, including cigarette smoking,
male gender, higher HAQ score, genetic predisposition,
the presence of other extra-articular manifestations of
RA and treatment with methotrexate [6,12,17,44-46].
In contrast to previous studies, ours is the first study to
e x c l u d e  p a t i e n t s  w i t h  c l i n i c a l l y  a p p a r e n t  C V D ,  t h u s
increasing the likelihood that the reported respiratory
symptoms truly reflected lung disease, rather than car-
diac disease. Furthermore, to control for confounding by
subclinical CVD, we adjusted for the severity of subclini-
cal CAD in our analyses. We found no statistically signifi-
cant association between subclinical CAD and PFT
abnormalities in our population. Furthermore, the associ-
ation between pulmonary symptoms and PFT abnormali-
ties was not affected after adjusting for subclinical CAD.
The present study differs from previously described
cohorts in a number of other important matters. Because
this analysis is nested in a larger ongoing natural history
study, our patient cohort is extensively characterized with
available demographic, lifestyle and anthropometric
information. The number of subjects is considerably
larger than in previous studies. Measures of functionality
(beyond the HAQ score) are available, including accurate
recording of exercise. Patients with RA may be physically
deconditioned, and this may interfere with recognition of
respiratory symptoms. The information available in our
study allowed us to address this potential confounder as
both HAQ scores and reported exercise were included
and neither demonstrated a significant effect in multivar-
iable modeling.
There are some notable limitations in our study. PFTs
are not the gold standard for detecting respiratory dis-
ease. We chose to use PFTs rather than computed tomog-
raphy scans as our marker of lung disease in this analysis
a s  t h e y  p r o v i d e  a  c o m m o n  a n d  l o w - r i s k  d i a g n o s t i c
modality that often precedes radiographic evaluation in
clinical practice. We believe that using a more sensitive
imaging method might strengthen our associations by
identifying parenchymal abnormalities in patients who
Table 5: Receiver operator curve validation of multivariable models predicting the presence of specific PFT abnormalities
Characteristics included in model Full cohort (n = 159) Cohort excluding reported lung disease (n = 129)
AUC 95% CIa P value AUC 95% CIa P value
Model predicting restriction
Pulmonary symptoms only 0.66 (0.51 to 0.81) - 0.63 (0.51 to 0.80) -
Symptoms + other factorsb 0.79 (0.59 to 0.92) 0.046* 0.79 (0.61 to 0.92) 0.040*
Model predicting obstruction
Pulmonary symptoms only 0.62 (0.50 to 0.74) - 0.62 (0.51 to 0.75) -
Symptoms + other factorsc 0.91 (0.78 to 0.98) 0.0001* 0.86 (0.75 to 0.94) 0.0005*
Symptoms + factors + lung disease 0.96 (0.91 to 0.99) 0.080** - - -
Model predicting impaired diffusion
Pulmonary symptoms only 0.66 (0.58 to 0.73) - 0.66 (0.57 to 0.75) -
Symptoms + other factorsd 0.85 (0.75 to 0.93) 0.0003* 0.85 (0.73 to 0.93) 0.001
Symptoms + factors + lung disease 0.86 (0.74 to 0.94) 0.41** - - -
PFT, pulmonary function test. a95% confidence interval (CI) obtained with repeated sampling and calculation of area under the curve (AUC) for 
1,000 bootstrap resamples with replacement. bOther factors included were those from the final predictive multivariable model (body mass index 
and current prednisone use). cOther factors included were those from the final predictive multivariable model (gender, exercise, current smoking, 
body mass index, presence of rheumatoid factor, and current prednisone use). dOther factors included were those from the final predictive 
multivariable model (age, current smoking, body mass index, and current prednisone use). *P values represent the comparison of AUC functions 
for the symptoms + other factors model vs. the symptom-only model. **P values represent the comparison of AUC functions for the symptoms 
+ factors + lung disease model vs. the symptoms + factors model.Pappas et al. Arthritis Research & Therapy 2010, 12:R104
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reported symptoms but were found to have normal PFTs.
The small number of patients with lung disease in this
cohort results in large confidence intervals in multivari-
ate analysis. This points to the need for replication of
these findings in a larger patient population.
There may have been an unintentional selection bias
against patients with significant lung disease who may
have elected not to participate in our study. In this case,
however, we would expect to observe stronger associa-
tions between symptoms and PFT abnormalities had
such patients participated. Furthermore, in the current
study, coronary artery scanning occurred 1.3 to 2.5 years
before pulmonary function testing. This might have lead
to an underestimation of coronary disease that developed
in the intervening time. Finally, our results may not be
completely applicable in practice where RA patients with
clinically significant CVD are more common. In a popu-
lation with a higher frequency of CVD, respiratory symp-
toms may be less specific to pulmonary disease. This can
only be addressed by a larger study in a population not
restricted for clinically significant CVD.
Conclusions
In summary, we observed a high prevalence of PFT
abnormalities in a selected population of RA patients and
a considerable frequency of respiratory symptoms as
assessed by a formal questionnaire. Respiratory symp-
toms and specific patient characteristics were identified
as predictors of lung disease as determined by PFT s. It
has been suggested that early identification and timely
therapeutic intervention with antifibrotic agents may
alter the prognosis of pulmonary fibrosis [17,46,47]. Sim-
ilarly, early intervention in patients with RA and chronic
obstructive pulmonary disease might improve quality of
life and performance status. A practical, cost-effective
way of identifying early pulmonary disease in patients
with RA could yield significant benefit in patient out-
comes. This study suggests a limited set of questions
could be incorporated into clinical practice that would
provide guidance regarding which patients should
undergo subsequent pulmonary function testing and
radiographic imaging. These findings may be of clinical
benefit if confirmed in a larger population study.
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